RxDoctor Payments Data

Paul Lyons, MD

Clinical Neurophysiology · Winchester, VANPI 1083656250

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $115,359 of the $171,434 with a category attached, or 67.3%. 60 manufacturers reported payments, led by UCB, Inc. at 49.7% of the total.

$171,434in general payments, 2019–2025

Across 1,141 payments — averaging $150.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$85K
  • SK Life Science, Inc.$26K
  • Greenwich Biosciences, Inc.$19K
  • Jazz Pharmaceuticals Inc.$12K
  • Livanova USA, Inc.$11K
  • Neurelis, Inc.$5K
  • plus $13K from 54 others
$533,861in research payments, 2019–2025

Across 116 payments — averaging $4602.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GW Research Limited$296K
  • Janssen Research & Development, LLC$89K
  • Livanova USA, Inc.$75K
  • SK Life Science, Inc.$31K
  • Jazz Pharmaceuticals Inc.$24K
  • UCB SA$19K

What the payments were for

  • Consulting fees$13,4208%
  • Speaking & faculty fees$115,35967%
  • Travel & lodging$17,94110%
  • Food & beverage$24,39114%
  • Education$3220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.231$85,277
SK Life Science, Inc.68$25,793
Greenwich Biosciences, Inc.55$19,000
Jazz Pharmaceuticals Inc.58$11,729
Livanova USA, Inc.28$11,128
Neurelis, Inc.26$5,497
AbbVie(2 entities)96$1,303
Biogen59$953
Lilly USA, LLC37$724
Novartis31$634
AstraZeneca(2 entities)29$625
Eisai Inc.31$604
Pfizer63$578
Amgen(2 entities)22$499
Supernus Pharmaceuticals, Inc.27$455
Neuropace, Inc.5$447
Sanofi22$438
Lundbeck LLC24$422
Teva Pharmaceuticals USA, Inc.22$416
Medtronic3$269
Inspire Medical Systems, Inc.7$244
ANI Pharmaceuticals, Inc.9$240
Genentech USA, Inc.22$227
Sunovion Pharmaceuticals Inc.13$209
EMD Serono, Inc.8$182
MDD US Operations, LLC3$179
Tanabe Pharma America, Inc.8$170
Abbott6$149
Cadwell Industries, Inc3$143
Amneal Pharmaceuticals LLC6$141
Microtransponder, Inc.1$139
Bristol Myers Squibb9$133
Catalyst Pharmaceuticals, Inc.6$133
TG Therapeutics, Inc.6$132
Biocodex, Inc.2$132
Argenx US, Inc.5$127
Kyowa Kirin, Inc.6$120
Acorda Therapeutics, Inc7$119
CSL Behring5$116
Avanir Pharmaceuticals, Inc.7$112
Mallinckrodt Hospital Products Inc.4$107
ZOLL Respicardia, Inc.1$107
Merz Pharmaceuticals, LLC4$90
Harmony Biosciences LLC4$89
Monteris Medical Corporation1$88
Zogenix Inc.2$86
Grifols USA, LLC5$75
Sumitomo Pharma America, Inc.4$74
Biohaven Pharmaceutical Holding Company Ltd.4$74
GE HealthCare3$65
Axsome Therapeutics, Inc.3$65
Vanda Pharmaceuticals Inc.2$60
Otsuka America Pharmaceutical, Inc.3$55
Johnson & Johnson3$54
Aquestive Therapeutics, Inc.2$49
Neurocrine Biosciences, Inc.3$40
Immedica Pharma US, Inc.2$39
Acadia Pharmaceuticals Inc2$37
Adamas Pharmaceuticals, Inc.2$32
E.r. Squibb & Sons, L.L.C.1$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$228,275
Medicare patients
718
Services billed
3,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)93$521,769
XcopriCenobamate39$67,804
BotoxOnabotulinumtoxina22$29,261
LamictalLamotrigine18$28,748
Nurtec OdtRimegepant Sulfate18$18,964
Rufinamide17$15,943
Levetiracetam108$2,877
Felbamate11$2,417
Lamotrigine61$1,925
Memantine Hcl22$877
Zonisamide15$617
Trazodone Hcl15$611
Duloxetine Hcl12$536
Topiramate46$477
Donepezil Hcl61$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$25,793$67,80439 claims
AbbVieBotox$1,303$29,26122 claims
PfizerNurtec Odt$578$18,96418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →